In Good Company with Nicolai Tangen Lars Fruergaard Jørgensen CEO of Novo Nordisk
Mar 15, 2023
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, explains the critical issue of obesity as a complex disease influenced by numerous factors. He discusses innovative drug developments that aid in both diabetes and obesity management, emphasizing their benefits and the challenges of access in Europe. Jørgensen also shares insights on navigating cultural dynamics in leadership and the importance of supporting non-linear career paths for young professionals. His vision blends corporate responsibility with a commitment to equitable healthcare access.
AI Snips
Chapters
Transcript
Episode notes
Obesity: A Complex Disease
- Obesity is a complex disease driven by easy access to processed foods, reduced physical activity, and genetic predisposition.
- It's now recognized as a disease, not just a lifestyle issue, influenced by genetics and physiology.
Childhood Obesity: A Growing Concern
- Childhood obesity is a growing concern, increasing the risk of lifelong struggles and societal challenges.
- Focusing on prevention through school systems and societal changes is crucial to reduce adult obesity.
Novo Nordisk's Weight-Loss Drug and Social Media
- Novo Nordisk's weight-loss drug went viral on TikTok, helped by Elon Musk.
- It addresses obesity by reducing appetite and has shown significant weight loss in clinical trials.